Also, after she received her COVID-19 vaccinations, she was sick for 9 weeks. Since on an unknown date in OCT/2021, she has been experiencing long haul symptoms of COVID-19; Also, after she received her COVID-19 vaccinations, she was sick for 9 weeks. Since on an unknown date in OCT/2021, she has been experiencing long haul symptoms of COVID-19; fter she received her COVID-19 vaccinations, she was sick for 9 weeks; This is a spontaneous report received from contactable reporter(s) (Consumer or other non-HCP) for a sponsored program via Amgen.  A 53-year-old female patient received bnt162b2 (BNT162B2) (Batch/Lot number: unknown) as dose number unknown, single for covid-19 immunisation. Relevant medical history included: "Rheumatoid arthritis" (ongoing). Concomitant medication(s) included: ENBREL taken for rheumatoid arthritis. The following information was reported: DRUG INEFFECTIVE (medically significant), SUSPECTED COVID-19 (medically significant) all with onset Oct2021, outcome "unknown" and all described as "Also, after she received her COVID-19 vaccinations, she was sick for 9 weeks. Since on an unknown date in OCT/2021, she has been experiencing long haul symptoms of COVID-19"; ILLNESS (non-serious) with onset 2021, outcome "unknown", described as "fter she received her COVID-19 vaccinations, she was sick for 9 weeks". The patient underwent the following laboratory tests and procedures: sars-cov-2 test: (2020) positive, had covid-19.  Additional information: This non-serious Solicited report (USASL2022010806) was reported to Amgen on 21/JAN/2022 by a consumer and involves a 53-year-old female patient who feels like her head is in a fog, she had covid 22 months/experiencing long haul symptoms of covid [PT: post-acute COVID-19 syndrome], she was sick for 9 weeks [PT: illness] while receiving Enbrel, Reusable Autoinjector. No historical medical condition was reported. The patient's current medical condition included rheumatoid arthritis. The patient's concomitant medications included COVID-19 (Coronavirus disease 19) vaccine. No co-suspect medications were reported. The patient began Enbrel, Reusable Autoinjector on an unknown date. On an unknown date in 2020, 22 months ago, the patient felt like her head was in a fog, since she had COVID-19 (Coronavirus disease 19) for 7 weeks. Also, after she received her COVID-19 vaccinations, she was sick for 9 weeks. Since on an unknown date in OCT/2021, she has been experiencing long haul symptoms of COVID-19. On 19/JAN/2022 after her injection with her auto touch device was completed, the low battery symbol appeared. She had a previous auto touch device replaced after one and half years due to the battery dying. Product Replacement request was for one auto touch device. No treatment information was received. The outcome of the events post-acute COVID-19 syndrome and illness were reported as unknown. Action taken with Enbrel, Reusable Autoinjector was reported as unknown for the events post-acute COVID-19 syndrome and illness. The causal relationship between the events post-acute COVID-19 syndrome, illness and Enbrel, Reusable Autoinjector were not provided by the consumer. Follow up has been requested.  The lot number for bnt162b2 was not provided and will be requested during follow up.